{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:09:20Z","timestamp":1789412960574,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022-82172287"],"award-info":[{"award-number":["2022-82172287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014125","name":"Fujian Provincial Health Commission","doi-asserted-by":"publisher","award":["2020CXA027"],"award-info":[{"award-number":["2020CXA027"]}],"id":[{"id":"10.13039\/501100014125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2019QH1014"],"award-info":[{"award-number":["2019QH1014"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["2019QH2007"],"award-info":[{"award-number":["2019QH2007"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bcp.2026.117673","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:10:59Z","timestamp":1767658259000},"page":"117673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors"],"prefix":"10.1016","volume":"245","author":[{"given":"Qiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-9766","authenticated-orcid":false,"given":"Zu-Chian","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjiao","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117673_b0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"6382","key":"10.1016\/j.bcp.2026.117673_b0010","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"issue":"6230","key":"10.1016\/j.bcp.2026.117673_b0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117673_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T Cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117673_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020200","article-title":"Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J. Clin. Med."},{"issue":"18","key":"10.1016\/j.bcp.2026.117673_b0035","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.117673_b0040","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117673_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.bcp.2026.117673_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310430","article-title":"PD1CD28 chimeric molecule enhances EGFRv\u2162 specific CAR-T cells in xenograft experiments in mouse models","volume":"19","author":"Chen","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.117673_b0060","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3389\/fimmu.2019.00780","article-title":"Corrigendum: chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"10","author":"Mirzaei","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117673_b0065","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0075","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117673_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117673_b0090","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2026.117673_b0095","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.117673_b0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117673_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.117673_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618404","article-title":"IL-7 armed binary CAR T cell strategy to augment potency against solid tumors","volume":"16","author":"Torres Chavez","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0115","doi-asserted-by":"crossref","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","article-title":"Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2026.117673_b0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8047","key":"10.1016\/j.bcp.2026.117673_b0125","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41420-023-01626-4","article-title":"Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-gamma promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors","volume":"9","author":"Fang","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bcp.2026.117673_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omto.2023.08.009","article-title":"Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL","volume":"30","author":"Zhou","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0140","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117673_b0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bcp.2026.117673_b0150","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117673_b0160","article-title":"Overexpression of B7-H3 is associated with poor prognosis in laryngeal cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117673_b0165","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.117673_b0170","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.117673_b0175","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1021\/acsnano.2c12217","article-title":"Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy","volume":"17","author":"Fan","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.117673_b0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"8","key":"10.1016\/j.bcp.2026.117673_b0185","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2026.117673_b0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117673_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.857927","article-title":"Development of novel CD47-specific ADCs possessing high potency against non-small cell lung cancer in vitro and in vivo","volume":"12","author":"Chiang","year":"2022","journal-title":"Front. Oncol."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.117673_b0260","article-title":"Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects","volume":"310","author":"Chiang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117673_b0265","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.148247","article-title":"Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy","volume":"7","author":"Hu","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.117673_b0270","doi-asserted-by":"crossref","DOI":"10.2174\/0113892010319495241218114812","article-title":"Strengthening effect of thalidomide combined with an Anti-PD1 antibody on enhancing immunity for lung cancer therapy","author":"Liu","year":"2025","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2026.117673_b0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.bcp.2026.117673_b0205","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.117673_b0215","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.bcp.2026.117673_b0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13578-016-0098-2","article-title":"IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia","volume":"6","author":"Xu","year":"2016","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bcp.2026.117673_b0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molimm.2019.11.011","article-title":"Control of memory CD8(+) T cell longevity and effector functions by IL-15","volume":"117","author":"Nolz","year":"2020","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117673_b0230","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2026.117673_b0235","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fcell.2019.00212","article-title":"CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention","volume":"7","author":"Yan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0240","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117673_b0245","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W","volume":"32","author":"Alt","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117673_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:24:10Z","timestamp":1781699050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S0006295226000043"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117673","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117673"}}